Observation #1: While NASEM confirmed Haystack’s long-held belief of “outsized impact” to rare disease patients from the?inextricable link between FDA processes, pricing and payer decisions,?nothing in the statute directed NASEM to conflate access, pricing, and payer decisions in the study Congress required of them. We oppose efforts to begin cost containment needed across the US health care system with children dying of rare diseases. https://lnkd.in/ekCjpdpm
关于我们
The Haystack Project is committed to the Rare and Ultra Rare Disease Community. It brings together Innovators, Patients and Caregivers to educate and advocate for reimbursement policies that recognize the unique circumstances of extremely rare conditions and treatments.
- 网站
-
https://haystackproject.org/
Haystack Project的外部链接
- 所属行业
- 公共政策
- 规模
- 2-10 人
- 总部
- Washington,DC
- 类型
- 非营利机构
- 创立
- 2016
- 领域
- Rare Disease、Reimbursement、Policy、Drug Development、Clinical Trials、FDA、Access、Orphan Drug、PFDD、Healthcare、Rare Cancer、ICER、Regulations和Insurance
地点
-
主要
US,DC,Washington,20007
Haystack Project员工
-
Lisa Steelman, MBA
Executive Leader | Advocate | Business Development, Public Affairs & Government Relations | Association Management | Interim Consultant | CHIEF member
-
B. Scott Muench
Vice President of Customer Experience
-
Lynn Taylor
Global Corporate Affairs Executive | Breakthrough Leader | Board Member
-
Kara Krzan Berasi, PharmD, MS
CEO at Haystack Project | Rare Disease Advocate
动态
-
CEO of Haystack Project, Kara Berasi, provides public comment at the Advancing Rare Disease Therapies Through an FDA Rare Disease Innovation Hub https://lnkd.in/g-Q3TQXN
-
Finishing up the week by highlighting another article surrounding our Capitol Hill event https://lnkd.in/eFyshN2m
-
Haystack Project, whose membership comprises rare and ultra-rare disease patient advocacy organizations, also raised concerns about the draft guidance’s language on waivers. ? “Several of Haystack Project’s member organizations expressed concerns with FDA’s stated intentions on DAP waivers and suggested that FDA implement a presumption that studies in populations with fewer than 2,000 patients would qualify for a waiver,” the group’s?comments?state. “The final guidance should also include details and examples illustrating its view on instances for which a DAP would be impracticable.” https://lnkd.in/e9Sug-np
-
Haystack Project in the news!
Haystack Project in the news on the heels of a great event last week. If you weren't able to make it, stay tuned for the recording you can listen to on your commute/morning walk... https://lnkd.in/ebKxsKG9
-
Haystack Project in the news on the heels of a great event last week. If you weren't able to make it, stay tuned for the recording you can listen to on your commute/morning walk... https://lnkd.in/ebKxsKG9
-
RSVP Link is LIVE: https://lnkd.in/eGMxej_F
-
This one you don’t want to miss!
Registration Link is LIVE https://lnkd.in/eD6e_k44 We hope to see you there!